Please try another search
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Name | Age | Since | Title |
---|---|---|---|
Dennis Arthur Ausiello | 75 | 2018 | Independent Director |
Andrew Farquharson | 52 | 2012 | Director |
Mir A. Imran | 65 | 2021 | Executive Chairman |
Maulik Nanavaty | 59 | 2016 | Independent Director |
Lisa Ann Rometty | - | 2022 | Non-Employee Director |
Lisa Ann Rometty | 55 | 2022 | Independent Director |
Jean-Luc Butel | 67 | 2021 | Independent Director |
Laureen DeBuono | 65 | 2021 | Lead Independent Director |
Talat Imran | 41 | 2021 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review